{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:29:44Z","timestamp":1791725384352,"version":"4.3.4"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,17]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Psoriatic arthritis (PsA) is a chronic inflammatory condition characterized by joint involvement, enthesitis, dactylitis, and skin psoriasis. The pathophysiology of PsA is complex, driven by dysregulated immune responses, making targeted therapies essential for managing symptoms. Despite the success of biologic disease-modifying anti-rheumatic drugs (bDMARDs) like tumor necrosis factor (TNF) inhibitors, many patients experience suboptimal responses or adverse effects, necessitating the development of new therapies. Emerging biologics targeting interleukin (IL)-17, IL-23, and Janus kinase (JAK) pathways offer promising alternatives. This review aims to evaluate the efficacy and safety of emerging biologics for PsA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A systematic review of studies published from 2000 to December 2024 was conducted. Randomized controlled trials (RCTs), cohort studies, and clinical trials were included to assess the efficacy, safety, and adverse effects of bDMARDs and targeted synthetic DMARDs (tsDMARDs) for PsA treatment. Studies focusing on other aspects of psoriasis or nonpharmacological treatments were excluded. Key data extracted included study design, treatment type, efficacy measures (e.g., ACR response), and safety outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 20 studies involving 77,124 participants were reviewed. Biologic DMARDs such as TNF inhibitors, IL-17 inhibitors (e.g., secukinumab, ixekizumab), and IL-23 inhibitors (e.g., guselkumab) showed high efficacy in managing both joint and skin symptoms. Emerging therapies like bimekizumab (targeting IL-17A and IL-17F) demonstrated enhanced efficacy compared to traditional biologics. Conventional DMARDs, such as cyclosporine and leflunomide, were less effective but still showed moderate benefits. Safety profiles were generally favorable, with biologics showing fewer adverse effects than conventional therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Emerging biologics have significantly advanced the management of PsA, offering greater efficacy and safety compared to conventional DMARDs. IL-17 and IL-23 inhibitors, along with newer agents like bimekizumab, present promising treatment options for patients with inadequate responses to TNF inhibitors. Personalized treatment strategies, based on disease phenotype and individual patient needs, are essential for optimizing outcomes in PsA management. Further research into long-term efficacy and safety is required to refine treatment protocols and improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000045259","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:03:14Z","timestamp":1762210994000},"page":"e45259","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Emerging biological therapies for psoriatic arthritis: A systematic review"],"prefix":"10.1097","volume":"104","author":[{"given":"Saman","family":"Firdous","sequence":"first","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Amjad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Umair","family":"Choudhary","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Waqas","family":"Afzal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana Hamza","family":"Tayyab","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3310-5442","authenticated-orcid":false,"given":"Abida","family":"Parveen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260915","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.3390\/ijms24054901","article-title":"Psoriatic arthritis: pathogenesis and targeted therapies.","volume":"24","author":"Azuaga","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R2-20260915","doi-asserted-by":"crossref","first-page":"1759720X241295920","DOI":"10.1177\/1759720X241295920","article-title":"The impact of psoriatic arthritis on quality of life: a systematic review.","volume":"16","author":"James","year":"2024","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R3-20260915","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3390\/biomedicines9111511","article-title":"Psoriasis as an immune-mediated and inflammatory systemic disease: from pathophysiology to novel therapeutic approaches.","volume":"9","author":"Campanati","year":"2021","journal-title":"Biomedicines"},{"key":"R4-20260915","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.berh.2018.12.002","article-title":"An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis.","volume":"32","author":"So","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R5-20260915","doi-asserted-by":"crossref","first-page":"11662","DOI":"10.3390\/ijms241411662","article-title":"Inflammatory cytokines in psoriatic arthritis: understanding pathogenesis and implications for treatment.","volume":"24","author":"Lee","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R6-20260915","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1111\/bcp.14075","article-title":"The association between medication non-adherence and adverse health outcomes in ageing populations: a systematic review and meta-analysis.","volume":"85","author":"Walsh","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"R7-20260915","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1517\/14712598.2016.1118045","article-title":"Novel approaches to biological therapy for psoriatic arthritis.","volume":"16","author":"Boyd","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"R8-20260915","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/1744666X.2019.1631798","article-title":"Biological therapy in the treatment of psoriatic arthritis: economic and epidemiological considerations.","volume":"15","author":"da Silva","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"R9-20260915","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"R10-20260915","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R11-20260915","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1093\/rheumatology\/kead455","article-title":"Biologic disease-modifying anti-rheumatic drugs are equally effective in psoriatic arthritis patients with low and high joint counts.","volume":"63","author":"M\u00f6ller","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"R12-20260915","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/acr2.11156","article-title":"Long-term safety and tolerability of apremilast versus placebo in psoriatic arthritis: a pooled safety analysis of three phase III, randomized, controlled trials.","volume":"2","author":"Mease","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"R13-20260915","first-page":"869","article-title":"Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).","volume":"35","author":"Antoni","year":"2008","journal-title":"J Rheumatol"},{"key":"R14-20260915","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1136\/annrheumdis-2021-222027","article-title":"Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure.","volume":"81","author":"Deodhar","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R15-20260915","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40264-019-00797-3","article-title":"Ustekinumab safety in psoriasis, psoriatic arthritis, and Crohn\u2019s disease: an integrated analysis of phase II\/III clinical development programs.","volume":"42","author":"Ghosh","year":"2019","journal-title":"Drug Saf"},{"key":"R16-20260915","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(18)30952-8","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.","volume":"391","author":"Deodhar","year":"2018","journal-title":"Lancet"},{"key":"R17-20260915","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/annrheumdis-2012-203046","article-title":"Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.","volume":"73","author":"Horneff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R18-20260915","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2310\/7750.2007.00006","article-title":"Efalizumab for the treatment of psoriatic arthritis.","volume":"11","author":"Papp","year":"2007","journal-title":"J Cutan Med Surg"},{"key":"R19-20260915","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R20-20260915","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R21-20260915","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.","volume":"34","author":"Genovese","year":"2007","journal-title":"J Rheumatol"},{"key":"R22-20260915","first-page":"2274","article-title":"A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis.","volume":"28","author":"Salvarani","year":"2001","journal-title":"J Rheumatol"},{"key":"R23-20260915","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40744-024-00680-3","article-title":"From psoriasis to psoriatic arthritis: decoding the impact of treatment modalities on the prevention of psoriatic arthritis.","volume":"11","author":"Watad","year":"2024","journal-title":"Rheumatol Ther"},{"key":"R24-20260915","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1136\/ard-2023-224431","article-title":"Bimekizumab treatment in biologic DMARD-na\u00efve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.","volume":"82","author":"Ritchlin","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R25-20260915","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/keac353","article-title":"Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE.","volume":"62","author":"Mease","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"R26-20260915","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/art.42010","article-title":"Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis.","volume":"74","author":"McInnes","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R27-20260915","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS).","volume":"81","author":"Coates","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R28-20260915","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/17512433.2017.1329009","article-title":"Tumor necrosis factor inhibitors in psoriatic arthritis.","volume":"10","author":"Mantravadi","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R29-20260915","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00063030-200519010-00006","article-title":"TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.","volume":"19","author":"Tobin","year":"2005","journal-title":"BioDrugs"},{"key":"R30-20260915","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s13555-021-00483-2","article-title":"Interleukin-17 and interleukin-23: a narrative review of mechanisms of action in psoriasis and associated comorbidities.","volume":"11","author":"Menter","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R31-20260915","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The Immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis.","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"R32-20260915","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/1744666X.2021.1967748","article-title":"Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis.","volume":"17","author":"Ali","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"R33-20260915","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special article: 2018 American College of Rheumatology\/national psoriasis foundation guideline for the treatment of psoriatic arthritis.","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R34-20260915","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1007\/s12325-023-02568-0","article-title":"Safety of IL-23 p19 inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis: a narrative review.","volume":"40","author":"Blauvelt","year":"2023","journal-title":"Adv Ther"},{"key":"R35-20260915","doi-asserted-by":"crossref","first-page":"13913","DOI":"10.3390\/ijms232213913","article-title":"Therapeutic utility and adverse effects of biologic disease-modifying anti-rheumatic drugs in inflammatory arthritis.","volume":"23","author":"Min","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R36-20260915","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bjd.20818","article-title":"Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.","volume":"186","author":"Gordon","year":"2022","journal-title":"Br J Dermatol"},{"key":"R37-20260915","doi-asserted-by":"crossref","first-page":"7492904","DOI":"10.1155\/2018\/7492904","article-title":"Are Janus kinase inhibitors superior over classic biologic agents in RA Patients?","volume":"2018","author":"Kotyla","year":"2018","journal-title":"Biomed Res Int"},{"key":"R38-20260915","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0268-960X(92)90007-D","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF): receptor biology, signal transduction, and neutrophil activation.","volume":"6","author":"Rapoport","year":"1992","journal-title":"Blood Rev"},{"key":"R39-20260915","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1007\/s13555-024-01302-0","article-title":"Long-term efficacy and safety of bimekizumab and other biologics in moderate to severe plaque psoriasis: updated systematic literature review and network meta-analysis.","volume":"14","author":"Warren","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R40-20260915","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.3390\/jcm12247503","article-title":"Interclass switch between IL17 and IL23 inhibitors in psoriasis: a real-life, long-term, single-center experience.","volume":"12","author":"Giordano","year":"2023","journal-title":"J Clin Med"},{"key":"R41-20260915","doi-asserted-by":"crossref","first-page":"e081860","DOI":"10.1136\/bmj-2024-081860","article-title":"Advances in the management of psoriatic arthritis in adults.","volume":"387","author":"Kharouf","year":"2024","journal-title":"BMJ"},{"key":"R42-20260915","doi-asserted-by":"crossref","first-page":"e001117","DOI":"10.1136\/rmdopen-2019-001117","article-title":"Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis.","volume":"6","author":"Ruyssen-Witrand","year":"2020","journal-title":"RMD Open"},{"key":"R43-20260915","doi-asserted-by":"crossref","first-page":"672515","DOI":"10.3389\/fphar.2021.672515","article-title":"From bed to bench and back: TNF-\u03b1, IL-23\/IL-17A, and JAK-dependent inflammation in the pathogenesis of psoriatic synovitis.","volume":"12","author":"Silvagni","year":"2021","journal-title":"Front Pharmacol"},{"key":"R44-20260915","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review.","volume":"21","author":"Kamata","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R45-20260915","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial.","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:02:34Z","timestamp":1789498954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":45,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045259","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"2025-05-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}